Inhibition of simian immunodeficiency virus by foamy virus vectors expressing siRNAs

被引:13
|
作者
Park, J
Nadeau, P
Zucali, JR
Johnson, CM
Mergia, A [1 ]
机构
[1] Univ Florida, Coll Vet Med, Dept Pathobiol, Gainesville, FL 32610 USA
[2] Univ Florida, Coll Med, Dept Med, Gainesville, FL 32610 USA
[3] Auburn Univ, Coll Vet Med, Dept Pathobiol, Auburn, AL 36849 USA
关键词
SFV-1; vector; SIV gene therapy; siRNA; rev; env; tat; nef;
D O I
10.1016/j.virol.2005.08.038
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Viral vectors available for gene therapy are either inefficient or suffer from safety concerns for human applications. Foamy viruses are nonpathogenic retroviruses that offer several unique opportunities for gene transfer in various cell types from different species. In this report, we describe the use of simian foamy virus type 1 (SFV-1) vector to examine the efficacy of therapeutic genes. Hairpin short-interfering RNA (siRNA) that targets the simian immunodeficiency virus (SIV) rev/env was placed under the control of the PolIII U6 snRNA promoter for expression and screened for silencing target genes using cognate target-reporter fusions. We have identified an effective siRNA (designated R2) which reduces the rev and env gene expression by 89% and 95%, respectively. Using the simian foamy virus type 1 (SFV-1) based vector, we delivered the MITI expressed R2 siRNA into cultured cells and challenged with SIV. The results show that the R2 siRNA is a potent inhibitor of SIV replication as determined by p27 expression and reverse transcriptase assays. Vectors based on a non-pathogenic SFV-1 vector may provide a safe and efficient alternative to Currently available vectors, and the SIV model will help devise protocols for effective anti-HIV gene therapy. (c) 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码:275 / 282
页数:8
相关论文
共 50 条
  • [21] Gene transfer with foamy virus vectors
    Trobridge, G
    Vassilopoulos, G
    Josephson, N
    Russell, DW
    GENE THERAPY METHODS, 2002, 346 : 628 - 648
  • [22] Reducing mobitization of simian immunodeficiency virus based vectors by primer comptementation
    Grunwald, T
    Pedersen, FS
    Wagner, R
    Überla, K
    JOURNAL OF GENE MEDICINE, 2004, 6 (02): : 147 - 154
  • [23] PURIFICATION AND CHARACTERIZATION OF SIMIAN FOAMY VIRUS POLYPEPTIDES
    BENZAIR, AB
    RHODESFEUILLETTE, A
    EMANOILRAVICOVITCH, R
    PERIES, J
    BIOLOGY OF THE CELL, 1982, 45 : 311 - 311
  • [24] Models for AIDS pathogenesis: simian immunodeficiency virus, simian-human immunodeficiency virus and feline immunodeficiency virus infections
    Overbaugh, J
    Luciw, PA
    Hoover, EA
    AIDS, 1997, 11 : S47 - S54
  • [25] Simian foamy virus infection in a blood donor
    Boneva, RS
    Grindon, AJ
    Orton, SL
    Switzer, WM
    Shanmugam, V
    Hussain, AI
    Bhullar, VB
    Chamberland, ME
    Heneine, W
    Folks, TM
    Chapman, LE
    TRANSFUSION, 2002, 42 (07) : 886 - 891
  • [26] Foamy virus vectors for gene transfer
    Trobridge, Grant D.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2009, 9 (11) : 1427 - 1436
  • [27] Simian Foamy Virus Co-Infections
    Murray, Shannon M.
    Linial, Maxine L.
    VIRUSES-BASEL, 2019, 11 (10):
  • [28] Infection Patterns of Simian Foamy Virus in Macaques
    Dubosc, Julie
    Okamoto, Munehiro
    MacIntosh, Andrew
    FOLIA PRIMATOLOGICA, 2017, 88 (02) : 102 - 102
  • [29] Studies of Simian foamy virus transmission by blood
    不详
    JOURNAL OF MEDICAL PRIMATOLOGY, 2005, 34 (5-6) : 333 - 333
  • [30] First report of simian foamy virus in Asia
    Cooke, FJ
    Shapiro, DS
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2005, 9 (05) : 237 - 237